TQA-3810 / Sino Biopharm - LARVOL DELTA

Study on immune regulation and metabolic regulation of TLR8 receptor agonist TQA3810 (APASL 2025) - "TQA3810 significantly increases plasma IL-12 P40 levels and alters unsaturated fatty acid metabolism in healthy individuals, potentially linked to its role as a TLR8 agonist and its pro-inflammatory effects."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • IL12A • TLR8

FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF AN ORAL TOLL-LIKE RECEPTOR 8 AGONIST IN HEALTHY SUBJECTS (AASLD 2024) - "PartD was a drug-drug interaction (DDI) study to evaluate PK interactions between TQA3810 and Entecavir(ETV). TQA3810 was safe and well tolerated. TQA3810 can be taken with or without food. No DDI was observed between TQA3810 and ETV."

Clinical • P1 data • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pain • TLR8

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets (clinicaltrials.gov) - P1 | N=759 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation